Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz Acquires 20,000 Shares

Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz acquired 20,000 shares of Caribou Biosciences stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average cost of $1.02 per share, for a total transaction of $20,400.00. Following the completion of the transaction, the chief executive officer now directly owns 3,369,395 shares in the company, valued at $3,436,782.90. This trade represents a 0.60 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Caribou Biosciences Price Performance

Shares of CRBU stock opened at $1.02 on Tuesday. The company has a market capitalization of $94.87 million, a P/E ratio of -0.62 and a beta of 2.34. The company’s 50-day simple moving average is $1.35 and its two-hundred day simple moving average is $1.77. Caribou Biosciences, Inc. has a one year low of $0.98 and a one year high of $5.77.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. On average, research analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of CRBU. Centric Wealth Management bought a new position in shares of Caribou Biosciences during the fourth quarter valued at approximately $27,000. Erste Asset Management GmbH bought a new position in shares of Caribou Biosciences during the third quarter valued at approximately $28,000. Russell Investments Group Ltd. boosted its stake in shares of Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock valued at $38,000 after purchasing an additional 21,416 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Caribou Biosciences by 60.0% during the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after purchasing an additional 9,148 shares in the last quarter. Finally, Diametric Capital LP bought a new position in shares of Caribou Biosciences during the fourth quarter valued at approximately $42,000. 77.51% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on CRBU shares. Bank of America reduced their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup reduced their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.